- $290.11m
- $239.52m
- $152.55m
- 60
- 25
- 63
- 47
2019 December 31st | C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 12.5 | 37.3 | 92.9 | 119 | 153 |
Cost of Revenue | |||||
Gross Profit | 9.2 | 28.4 | 74.9 | 100 | 134 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 15.4 | 96 | 151 | 162 | 167 |
Operating Profit | -2.89 | -58.7 | -58.3 | -43.4 | -14.8 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -3.65 | -60.4 | -61.3 | -44.7 | -17.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -3.53 | -60.5 | -61.3 | -45 | -17.8 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -3.14 | -58.6 | -60.9 | -45.5 | -20.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.14 | -63.4 | -61.8 | -48.6 | -23.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.317 | -4.4 | -2.19 | -1.39 | -0.693 |